Contribute Information
Can you contribute information about this project?
Contact the EWS Team
According to the Bank’s website, the operation consists in a blended finance facility to support the investment by Biontech - a Rwandan based Promoter - to establish a mRNA-based vaccines manufacturing plant in Rwanda.
The aim is to support the promoter in establishing a regional research and development (R&D;) and manufacturing site for vaccines in Rwanda to strengthen the vaccine R&D; ecosystem across Africa.
The site will focus on the delivery of an African end-to-end commercial-scale manufacturing plant, initially producing an already approved vaccine with the intention of transferring other vaccines which are still in clinical development phase to address epidemic and pandemic threats.
The manufacturing plant will produce commercial vaccine products, including those currently under development, once approved. It will also operate as a Contract Manufacturing Organisation (CMO), serving African R&D; partners such as universities and private research institutions. The facility will manufacture products for clinical research purposes in compliance with good manufacturing practice (GMP) standards.
In addition to production, the operation includes capacity building activities to strengthen the capabilities of African R&D; partners and contribute to the development of the regional vaccine R&D; ecosystem.
The EIB will require the project's compliance with the relevant environmental legislation and alignment of the EIB's Environmental and Social principles and standards. Additional project activities, such as R&D, are expected to be carried out in existing facilities that are already used for similar purposes or are investments of intangible nature and hence are not expected to create significant impact on the environment.
A loan under EFSD+ Guarantee.
Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. BioNTech Rwanda, established in 2022, will manage the Kigali facility. To date, BioNTech has made a triple digit million Euro investment in the establishment of its mRNA manufacturing facility in Kigali and plans to continue investingover the next years.
| Private Actor 1 | Private Actor 1 Role | Private Actor 1 Sector | Relation | Private Actor 2 | Private Actor 2 Role | Private Actor 2 Sector |
|---|---|---|---|---|---|---|
| - | - | - | - | BioNTech SE | Client | - |
Contact: Antonie Kerwien
Email: a.kerwien@eib.org
Phone: + 352 4379-82175
ACCESS TO INFORMATION
You can submit an information request for project information at: https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm
ACCOUNTABILITY MECHANISM OF EIB
The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: http://www.eib.org/complaints/form via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf
When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces
